No headlines found.
Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4
ACCESS Newswire (Tue, 30-Dec 9:20 AM ET)
Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4
ACCESS Newswire (Tue, 23-Dec 9:29 AM ET)
ACCESS Newswire (Tue, 16-Dec 4:00 PM ET)
ACCESS Newswire (Mon, 15-Dec 8:00 AM ET)
Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended
ACCESS Newswire (Wed, 12-Nov 9:10 AM ET)
4 Clinical-Stage Biotechs to Watch as the Sector Rebounds (MDCX, AUPH, LEXX, EDSA)
AB Digital Inc (Thu, 23-Oct 3:11 PM ET)
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
Lexaria Bioscience Corp. trades on the NASDAQ stock market under the symbol LEXX.
As of January 20, 2026, LEXX stock price declined to $0.74 with 77,599 million shares trading.
LEXX has a beta of 0.37, meaning it tends to be less sensitive to market movements. LEXX has a correlation of 0.00 to the broad based SPY ETF.
LEXX has a market cap of $18.31 million. This is considered a Sub-Micro Cap stock.
Last quarter Lexaria Bioscience Corp. reported $174,000 in Revenue and -$.13 earnings per share. This beat revenue expectation by $104,000 and exceeded earnings estimates by $.03.
In the last 3 years, LEXX traded as high as $6.85 and as low as $.46.
The top ETF exchange traded funds that LEXX belongs to (by Net Assets): VXF.
LEXX has underperformed the market in the last year with a return of -62.7%, while the SPY ETF gained +15.8%. In the last 3 month period, LEXX fell short of the market, returning -10.8%, while SPY returned +2.9%. However, in the most recent 2 weeks LEXX has outperformed the stock market by returning +12.5%, while SPY returned -0.8%.
LEXX support price is $.69 and resistance is $.83 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LEXX shares will trade within this expected range on the day.